Rosiglitazone prevents amyloid-β oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 239-251

  Xu, Shujun ^a   Liu, Guilan ^a   Bao, Xiaoming ^b   Wu, Jie ^c   Li, Shaomin ^d   Zheng, Bangxu ^a   Anwyl, Roger ^e   Wang, Qinwen ^a  

^a NINGBO UNIVERSITY   (China)

^b NINGBO NO 2 HOSPITAL   (China)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; amyloid ; mitochondria; PPAR ; rosiglitazone; synapse formation; synapse plasticity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; OLIGOMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DENDRITE; DENDRITIC SPINE; ELECTROPHYSIOLOGICAL PROCEDURES; ELECTROPHYSIOLOGY; FILOPODIUM; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; HUMAN; IMMUNOCYTOCHEMISTRY; LONG TERM POTENTIATION; MITOCHONDRION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINE; SYNAPSE;

ALZHEIMER'S DISEASE; AMYLOID-Β; MITOCHONDRIA; PPARΓ; ROSIGLITAZONE; SYNAPSE FORMATION; SYNAPSE PLASTICITY;

AMYLOID BETA-PEPTIDES; ANILIDES; ANIMALS; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM AGENTS; DENDRITES; DENDRITIC SPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MITOCHONDRIA; NEURONAL PLASTICITY; NEURONS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PPAR GAMMA; RATS; RATS, WISTAR; SYNAPSES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84893957415     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130680     Document Type: Article

References (43)

1. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD, Rosiglitazone in Alzheimer's Disease Study Group (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6, 246-254.
2. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17, 561-567.
3. Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25, 2455-2462.
4. Tam JH, Pasternak SH (2012) Amyloid and Alzheimer's disease: Inside and out. Can J Neurol Sci 39, 286-298.
5. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058.
6. Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120(Suppl 1), 125-139.
7. Sakono M, Zako T (2010) Amyloid oligomers: Formation and toxicity of Abeta oligomers. FEBS J 277, 1348-1358.
8. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M, Pensalfini A, Soriaga AB, Landau M, Teng PK, Cascio D, Glabe C, Eisenberg D (2012) Atomic view of a toxic amyloid small oligomer. Science 335, 1228-1231.
9. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, LambertMP,Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24, 10191-10200.
10. Wang-Dietrich L, Funke SA, Kuhbach K,Wang K, Besmehn A, Willbold S, Cinar Y, Bannach O, Birkmann E, Willbold D (2013) The smyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease. J Alzheimers Dis 34, 985-994.
11. Selkoe DJ (2008) Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res 192, 106-113.
12. Wang Q,Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclindependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24, 3370-3378.
13. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8, 79-84.
14. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22, 6331-6335.
15. Nicolakakis N, Hamel E (2010) The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2, pii: 21. doi: 10.3389/fnagi.2010.00021
16. Luconi M, Cantini G, Serio M (2010) Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer? Steroids 75, 585-594.
17. Biessels GJ, Kappelle LJ, Utrecht Diabetic Encephalopathy Study G (2005) Increased risk of Alzheimer's disease in Type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33, 1041-1044.
18. Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A, Del Rio J, Frechilla D (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 1593-1604.
19. Cowley TR, O'Sullivan J, Blau C, Deighan BF, Jones R, Kerskens C, Richardson JC, Virley D, Upton N, Lynch MA (2012) Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP. Neurobiol Aging 33, 162-175.
20. Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15, 272-285.
21. Rodriguez-Rivera J, Denner L, Dineley KT (2011) Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 216, 255-261.
22. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958.
23. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
24. Xu S, Zhou S, Xia D, Xia J, Chen G, Duan S, Luo J (2010) Defects of synaptic vesicle turnover at excitatory and inhibitory synapses in Niemann-Pick C1-deficient neurons. Neuroscience 167, 608-620.
25. Geissler M, Faissner A (2012) A new indirect co-culture set up of mouse hippocampal neurons and cortical astrocytes on microelectrode arrays. J Neurosci Methods 204, 262-272.
26. Fiala JC, Feinberg M, Popov V, Harris KM (1998) Synaptogenesis via dendritic filopodia in developing hippocampal area CA1. J Neurosci 18, 8900-8911.
27. Di Loreto S, Balestrino M (1997) Development of vulnerability to hypoxic damage in in vitro hippocampal neurons. Int J Dev Neurosci 15, 225-230.
28. Rui Y, Gu J, Yu K, Hartzell HC, Zheng JQ (2010) Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: The mitochondrial contribution. Mol Brain 3, 10.
29. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L (2012) Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 109, E2895-E2903.
30. Ardiles AO, Tapia-Rojas CC, Mandal M, Alexandre F, Kirkwood A, Inestrosa NC, Palacios AG (2012) Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease. Proc Natl Acad Sci U S A 109, 13835-13840.
31. Jontes JD, Smith SJ (2000) Filopodia, spines, and the generation of synaptic diversity. Neuron 27, 11-14.
32. Brodbeck J, Balestra ME, Saunders AM, Roses AD, Mahley RW, Huang Y (2008) Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci U S A 105, 1343-1346.
33. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL(2009) Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976.
34. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
35. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello Russo C (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 70, 177-188.
36. Pardo R, Enguix N, Lasheras J, Feliu JE, Kralli A, Villena JA (2011) Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor gamma coactivator-1alpha. PLoS One 6, e26989.
37. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivationinduced neuronal cell loss. Neurochem Int 55, 496-504.
38. Wang X, Su B, Zheng L, Perry G, Smith MA, Zhu X (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 109(Suppl 1), 153-159.
39. Kimura R, Ma LY, Wu C, Turner D, Shen JX, Ellsworth K, Wakui M, Maalouf M, Wu J (2012) Acute exposure to the mitochondrial complex I toxin rotenone impairs synaptic long-term potentiation in rat hippocampal slices. CNS Neurosci Ther 18, 641-646.
40. Chiang MC, Cheng YC, Lin KH, Yen CH (2013) PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha. Neuroscience 229, 118-129.
41. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, doubleblind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30, 131-146.
42. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two phase 3 studies. Curr Alzheimer Res 8, 592-606.
43. Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM (2010) A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis 22, 1241-1256.